Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Domain Therapeutics
Domain Therapeutics
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Graphs and graph data science in drug discovery
Life sciences data expert Dr Alexander Jarasch discusses what work being done at the Institut de Recherches Servier can teach us about using modern data technologies for early...
Why smaller CDMOs should enhance their operational efficiency now: a CPHI expert guide
CPHI experts advise smaller CDMO's to invest in supply chain resilience, friend shoring and AI to keep up with the predicted uptick in funding for 2025
CPI collaborates with industry leaders to expedite drug manufacturing via digitisation
Digitising manufacturing technologies could allow enhanced ability to scale production, reduce costs and expedite the process
Janssen to adopt Johnson & Johnson brand as the company celebrates 100 years of UK operation
The company's pharmaceutical and medical technology segments will combine under the Johnson & Johnson brand name in the UK
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Ingredients
Domain makes two acquisitions for G Protein-Coupled Receptor programme
Prestwick Chemical and Neurofit are former subsidiaries of Australia-based Bionomics
Research & Development
Domain Therapeutics adds Sylvie Ryckebusch to Board
Ryckebusch joins Domain from Merck Serono
Media
Domain Therapeutics receives $125m to assign its intellectual property
Domain Therapeutics to receive up to $125 million for assignment of its intellectual property covering the Foliglurax mGluR4 PAM series discovered by a French biotech
Research & Development
Domain Therapeutics and Pfizer collaborate on bioSensAll
Technology will be used to profile signaling of mutant GPCRs to accelerate validation of novel GPCR drug targets
Finance
Merck will develop Domain Therapeutics next generation adenosine receptor programs
Domain Therapeutics and Merck enter into an agreement for development of adenosine receptor antagonists in immuno-oncology
Research & Development
Domain Therapeutics closes €2m funding round
Will use money to strengthen partnerships for discovering drugs targeting GPCRs
Research & Development
Domain Therapeutics wins €933,000 grant for schizophrenia project
French GPCR specialist will lead €5.1m ATHOS project
Subscribe now